Zevra Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Zevra Therapeutics, Inc. (ZVRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 5.78 million shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2024-04-01
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2015-03-31 was 5.33K shares.
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 5.78M shares, a 302.98% increase from fiscal 2022.
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.43M shares, a 56.00% increase from fiscal 2021.
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 919.38K shares, a 889.98% increase from fiscal 2020.
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 92.87K shares, a 95.95% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|
| 2023-12-31 | 5.78M shares 10-K · filed 2024-04-01 | |
| 2022-12-31 | 1.43M shares 10-K · filed 2023-03-07 | |
| 2021-12-31 | 919.38K shares 10-K · filed 2022-03-31 | |
| 2020-12-31 | 92.87K shares 10-K · filed 2021-03-12 | |
| 2019-12-31 | 2.29M shares 10-K · filed 2020-02-28 | |
| 2018-12-31 | 898.00K shares 10-K · filed 2019-03-01 | |
| 2017-12-31 | 919.00K shares 10-K · filed 2018-03-30 | |
| 2016-12-31 | 959.38K shares 10-K · filed 2017-03-10 | |
| 2015-12-31 | 1.01M shares 10-K · filed 2016-03-16 | |
| 2015-03-31 | 5.33K shares 10-Q · filed 2015-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |